effect
antivir
agent
urgent
need
combat
possibl
return
sever
acut
respiratori
syndrom
sar
commerci
antivir
agent
pure
chemic
compound
extract
tradit
chines
medicin
herb
screen
clinic
isol
sar
coronaviru
neutralis
test
confirm
plaqu
reduct
assay
leukocyt
interferonalpha
ribavirin
lopinavir
rimantadin
baicalin
glycyrrhizin
show
antivir
activ
two
interferon
activ
cell
line
preincub
drug
h
viral
inocul
result
confirm
plaqu
reduct
assay
antivir
activ
vari
use
differ
cell
line
checkerboard
assay
synergi
perform
show
combin
interferon
leukocyt
interferonalpha
ribavirin
synergist
sinc
clinic
toxic
profil
agent
well
known
consid
either
singli
combin
prophylaxi
treatment
sar
randomis
placebo
control
trial
futur
epidem
although
sar
epidem
success
contain
quarantin
infect
control
measur
presenc
viru
wild
game
food
anim
stock
laboratori
possibl
season
diseas
suggest
recurr
epidem
unlik
come
winter
sinc
age
group
affect
high
fatal
note
elderli
comorbid
donnelli
et
al
urgent
need
find
cure
prospect
clinic
viral
load
studi
nasopharyng
secret
sar
patient
show
viral
replic
peak
day
onset
symptom
subsequ
clinic
deterior
case
despit
decreas
viral
load
peiri
et
al
therefor
key
facet
manag
includ
respiratori
support
immunomodul
select
case
earli
institut
effect
antivir
agent
antivir
agent
given
earli
may
decreas
peak
viral
load
associ
immunodysregulatori
damag
moment
commerci
avail
antivir
agent
tailoredmad
sar
coronaviru
urgent
need
search
agent
known
use
clinic
toxic
profil
randomis
placebo
control
trial
conduct
epidem
recur
one
come
winter
report
studi
vitro
antivir
suscept
isol
sar
coronaviru
commerci
avail
antivir
agent
pure
chemic
compound
includ
baicalin
glycyrrhizin
chlorogen
acid
extract
tradit
chines
herb
ten
isol
sar
coronaviru
differ
sar
patient
satisfi
revis
criteria
sar
list
tabl
drug
use
antivir
suscept
specialist
draw
technic
scheme
tent
prevent
treatment
sever
acut
respiratori
syndrom
sar
use
tradit
chines
medicin
scheme
recip
qing
fei
jie
du
tang
soup
clear
lung
detoxif
recommend
consist
huang
qi
astragalu
membranaceu
gm
chai
hu
bupleurum
chinens
gm
huang
ephedra
sinica
gm
xing
ren
prunu
armeniaca
gm
sheng
gao
plaster
stone
gm
sheng
yi
ren
coix
lacrymajobi
gm
gua
wei
pi
benincasa
hispida
gm
jie
geng
platycodon
grandiflorum
gm
bo
mentha
haplocalyx
gm
huang
qin
scutellaria
baicalensi
gm
sheng
gan
cao
glycyrrhiza
uralensi
gm
jin
yin
hua
flo
lonicera
gm
qing
hao
artemisia
apiacea
gm
among
scutellaria
baicalensi
glycyrrhiza
uralensi
flo
lonicera
artemisia
apiacea
pure
chemic
defin
ingredi
extract
purifi
document
antimicrobi
activ
consequ
main
bioactiv
compound
name
baicalin
deriv
scutellaria
baicalensi
glycyrrhizin
glycyrrhiza
uralensi
chlorogen
acid
flo
lonicera
artesun
artemisia
apiacea
investig
present
studi
pharmacolog
properti
baicalin
glycyrrhizin
chlorogen
acid
summar
tabl
artesun
includ
tabl
sinc
alreadi
well
known
antimalari
drug
western
medicin
price
extract
previous
report
lu
et
al
concentr
baicalin
glycyrrhizin
glycyrrhizin
plasma
found
oral
administr
mg
glycyrrhizin
healthi
person
presum
glycyrrhizin
metabol
glycyrrhetin
acid
intestin
bacteria
contain
amount
consum
littl
trace
expect
mg
per
person
human
may
due
also
amount
consum
much
lower
anim
standard
dose
oral
administr
human
mg
baicalin
tablet
also
mg
baicalin
calcul
herb
assum
g
herb
use
herb
may
contain
baicalin
mg
glycyrrhizin
tablet
mg
glycyrrhizin
calcul
herb
assum
herb
contain
glycyrrhizin
mg
calcul
herb
assum
herb
contain
chlorogen
acid
serum
level
intraven
administr
chlorogen
acid
lopinavir
cell
cultur
system
also
monitor
hplc
lu
et
al
wherea
concentr
other
monitor
neutral
assay
vesicular
stomat
viru
indiana
strain
laboratori
strain
influenza
procedur
use
vitro
antivir
suscept
test
follow
initi
screen
compound
prototyp
sar
coronaviru
strain
perform
microtitr
plate
seed
foetal
rhesu
cell
twofold
dilut
antivir
agent
start
four
time
peak
serum
concentr
maximum
therapeut
dose
less
onequart
trough
serum
concentr
test
quadrupl
tcid
sar
coronaviru
correspond
set
cell
control
drug
without
viru
inocul
use
control
drug
toxic
cell
score
inhibit
cytopath
effect
cpe
h
compound
demonstr
vitro
inhibitori
activ
reassay
nine
strain
sar
coronaviru
collect
differ
patient
differ
hospit
hong
kong
special
administr
region
hksar
antivir
activ
also
compar
foetal
rhesu
cell
line
like
clinic
signific
inhibitori
activ
test
plaqu
reduct
assay
select
agent
consist
activ
plaqu
reduct
assay
checkerboard
assay
synergi
perform
combin
interferon
ribavirin
use
neutral
test
well
microtit
plate
seed
vero
cell
line
cell
incub
interferon
viral
inocul
vero
cell
use
instead
vero
cell
line
better
antivir
effect
demonstr
vero
less
two
cell
line
ribavirin
interferon
ten
isol
sar
coronaviru
differ
patient
sar
admit
differ
hospit
hksar
show
seroconvers
toward
prototyp
viru
infect
cell
line
use
studi
tabl
isol
lung
tissu
biopsi
prototyp
viru
urin
nasopharyng
aspir
initi
screen
commerci
avail
antimicrobi
agent
prototyp
viru
grown
cell
line
reveal
inhibitori
activ
acyclovir
ganciclovir
cidofovir
foscarnet
amantadin
zidovudin
stavudin
nevirapin
abacavir
ritonavir
inhibitori
activ
detect
glycyrrhizin
artesun
chlorogen
acid
cell
line
glycyrrhizin
still
includ
test
report
activ
cell
line
cinatl
et
al
test
neutral
test
tabl
comparison
antivir
activ
compound
strain
sarscov
cell
line
prototyp
strain
isol
sar
coronaviru
activ
compound
confirm
detect
inhibitori
activ
leukocyt
interferonalpha
ribavirin
lopinavir
rimantadin
baicalin
rang
effect
concentr
compound
requir
reduc
plaqu
form
unit
ec
h
select
index
shown
tabl
neutral
test
compound
run
cell
line
rimandatin
glycyrrhizin
leukocyt
interferonalpha
interferonbeta
activ
especi
h
moreov
preincub
cell
line
two
interferon
h
ad
viru
markedli
enhanc
inhibitori
activ
three
ribavirin
lopinavir
baicalin
less
activ
cell
line
tabl
plaqu
reduct
assay
vero
cell
line
use
instead
vero
cell
line
antivir
activ
demonstr
agent
leukocyt
interferonalpha
lopinavir
ribavirin
rimantadin
baicalin
test
ec
uml
leukocyt
interferonalpha
uml
lopinavir
gml
ribavirin
gml
rimantadin
gml
baicalin
gml
compar
result
obtain
cpe
assay
test
synerg
ribavirin
lopinavir
alreadi
report
chu
et
al
synerg
could
demonstr
rimantadin
ribavirin
activ
compound
interferon
thu
checkerboard
assay
perform
combin
leukocyt
interferonalpha
ribavirin
mark
synerg
seen
h
combin
leukocyt
interferonalpha
gml
ribavirin
gml
gml
ribavirin
gml
shown
activ
h
incub
tabl
control
sar
may
achiev
epidemiolog
measur
antivir
prophylaxi
treatment
vaccin
last
pandem
sar
avail
mean
control
public
health
measur
isol
suspect
case
quarantin
contact
person
protect
infect
control
procedur
highrisk
individu
health
care
worker
urgent
need
find
effect
antivir
agent
accept
side
effect
profil
develop
countri
china
commerci
avail
western
antivir
medicin
unlik
afford
peopl
moreov
sar
mortal
mainland
china
compar
favour
area
china
also
place
tradit
chines
medicin
herb
extens
use
treatment
sar
develop
vaccin
take
much
longer
time
therefor
undertook
antivir
suscept
test
commerci
avail
antivir
agent
hksar
pure
chemic
purifi
tradit
chines
herb
known
antimicrobi
activ
chosen
herb
includ
standard
formula
use
treatment
sar
china
hksar
interferonbeta
glycyrrhizin
report
signific
antivir
activ
sar
coronaviru
cinatl
et
al
b
use
cell
line
shown
ribavirin
rimantadin
lopinavir
baicalin
also
detect
antivir
activ
howev
like
interferon
glycyrrhizin
activ
tend
decreas
incub
beyond
h
tabl
judg
achiev
serum
level
standard
oral
parenter
dose
rimantadin
ribavirin
glycyrrhizin
even
two
interferon
unlik
clinic
signific
vivo
activ
moreov
lopinavir
rimantadin
rel
inferior
select
index
upon
subsequ
test
cell
line
leukocyt
interferonalpha
activ
especi
preincub
h
viral
inocul
find
suggest
prophylaxi
interferon
consid
though
ribavirin
much
less
activ
vero
cell
line
highli
synergist
either
two
interferon
therefor
combin
ribavirin
either
two
interferon
consid
treatment
sar
interferongamma
report
possess
antivir
activ
sar
coronaviru
cinatl
et
al
wherea
interferonbeta
confirm
activ
studi
interest
demonstr
activ
leukocyt
interferonalpha
despit
lack
activ
recombin
unexpect
prepar
leukocyt
interferonalpha
multisubtyp
natur
interferon
predominantli
interferon
contrast
commerci
prepar
singl
subtyp
recombin
vitro
studi
differ
subtyp
found
differ
antivir
activ
well
immunolog
effect
foster
et
al
also
demonstr
leukocyt
interferonalpha
superior
antivir
effect
recombin
interferon
human
immunodefici
viru
infect
fan
et
al
import
know
vitro
find
may
correspond
clinic
efficaci
despit
vitro
activ
topic
system
interferonalpha
produc
consist
reduct
symptom
lesion
durat
genit
herp
eron
et
al
lebwohl
et
al
interferonalpha
effect
prevent
cmv
infect
treat
cmv
pneumonia
bone
marrow
transplant
patient
meyer
et
al
despit
broadspectrum
antivir
activ
respiratori
virus
vitro
prophylact
intranas
interferonalpha
protect
rhinovirusinduc
common
cold
natur
condit
dougla
et
al
unexpect
intranas
leucocyt
recombin
interferonalpha
protect
experiment
human
infect
rhinoviru
coronaviru
respiratori
syncyti
viru
hayden
gwaltney
higgin
et
al
higgin
et
al
besid
high
cost
interferon
high
incid
fever
flu
syndrom
initi
phase
administr
may
pose
confus
term
respons
treatment
wellknown
side
effect
pancytopenia
may
also
confus
marker
sar
activ
decreas
platelet
occasion
neutrophil
raanani
benbassat
although
interstiti
pneumon
bronchiol
obliteran
organis
pneumonia
rare
complic
prolong
use
interferon
karim
et
al
ogata
et
al
alway
fear
proinflammatori
effect
may
worsen
viral
pneumon
caus
sar
less
expens
option
baicalin
glycyrrhizin
may
consid
tradit
chines
medicin
use
antivir
prophylaxi
treatment
serum
level
mg
glycyrrhizin
oral
detect
even
mg
dose
intraven
administr
peak
serum
level
gml
still
ec
glycyrrhizin
although
oral
dose
gm
baicalin
achiev
serum
concentr
gml
intraven
administr
mg
dose
baicalin
human
achiev
peak
serum
concentr
gml
thu
intraven
baicalin
consid
treatment
randomis
placebo
control
trial
develop
countri
formul
avail
afford
baicalin
shown
inhibit
two
mechan
kitamura
et
al
li
et
al
level
cellular
entri
baicalin
conjug
select
chemokin
interfer
capac
activ
cellular
receptor
respect
two
corecpetor
essenti
element
infect
therefor
baicalin
inhibit
envprotein
mediat
fusion
hiv
cell
express
baicalin
also
known
inhibit
revers
transcriptas
probabl
interf
bind
viral
rna
rt
molecul
near
activ
site
enzym
term
prophylaxi
sar
short
effect
vaccin
intranas
leukocyt
interferonalpha
like
effect
howev
local
side
effect
nasal
irrit
decreas
complianc
could
also
consid
randomis
placebocontrol
trial
antivir
treatment
symptomat
sar
import
rapid
reliabl
diagnost
test
sinc
earli
institut
antivir
therapi
import
decreas
peak
viral
load
leukocyt
interferonalpha
plu
ribavirin
appear
effect
combin
sinc
interferon
may
effect
induc
antivir
state
uninfect
host
cell
first
h
combin
short
cours
ribavirin
appear
reason
also
reduc
side
effect
fluid
volum
associ
full
cours
ribavirin
despit
superior
interferon
vitro
assay
littl
clinic
data
use
treatment
acut
viral
respiratori
infect
human
thu
combin
ribavirin
lopinavirritonavir
still
consid
sinc
posit
clinic
data
alreadi
accumul
histor
control
treatment
trial
chu
et
al
